Retatrutide does not have a confirmed approval or launch date yet. As of October 2026 it is still investigational, and Eli Lilly plans to submit its application to the FDA in the first quarter of 2027. UCHealth says it is “unlikely to become available to patients until 2027 at the soonest,” and Noom projects approval in late 2027 or early 2028.
Will retatrutide be approved in 2026?
Not on the company’s current plan. Drugs.com reports that Lilly announced on July 23, 2026 that it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. A filing is not an approval. Drugs.com says FDA review can take up to about a year, depending on the type of review. Noom estimates a review of 10 to 12 months, which leads it to a realistic approval window of late 2027 or early 2028.
| Stage | What the reports say | Status as of October 2026 |
|---|---|---|
| Phase 3 trials | Lilly has reported results from five Phase 3 trials (drugs.com) | Topline results released; not yet peer-reviewed (UCHealth) |
| Filing with the FDA | BLA planned for the first quarter of 2027 (drugs.com, Noom) | Planned, not yet filed |
| FDA review | Up to about a year (drugs.com); 10 to 12 months (Noom) | Starts only after filing |
| FDA decision | Approval, rejection, or a request for more data (InCare) | No decision yet |
| Pharmacy availability | Reaching pharmacies “some months after that” approval (Noom) | No date set |
| Price | No price set; Lilly plans to reflect overall value (drugs.com, Noom) | Not announced |
The trial numbers are the reason the drug draws so much attention. Drugs.com reports that in TRIUMPH-1, adults with obesity or overweight who did not have diabetes lost an average of 28.3% of their body weight over 80 weeks on the highest dose studied. That figure covers people who stayed on treatment as planned, and drugs.com notes that results including everyone enrolled are usually a little lower. UCHealth notes the findings have not gone through peer review yet. The TRIUMPH-1 study listing on ClinicalTrials.gov shows the study as completed, and that listing describes the study rather than its results.
Is retatrutide available to buy now?
No. Drugs.com says retatrutide is available only to people enrolled in an active clinical trial who meet that trial’s eligibility criteria, and it cannot be bought in pharmacies or online. Drugs.com also says that under federal law retatrutide cannot be used in compounded medicines. Products sold online as “retatrutide” or “retatrutide peptide” are not legitimate, and drugs.com says they are not tested for safety, purity or correct dose. The National Academy of Medicine GLP-1 basics page says the FDA has not assessed compounded GLP-1 formulations for safety, effectiveness, or quality, and that some may be fraudulent.
Does Eli Lilly offer early access to retatrutide?
Yes, but it is narrow. Noom reports that on August 3, 2026, Eli Lilly confirmed it will let a limited number of people apply for retatrutide before FDA approval, through the FDA’s expanded access pathway. Noom lists these criteria:
- Age 18 or older
- A BMI of 35 or more despite adherence to and tolerance of the highest available dose of an approved obesity therapy
- At least two serious or life-threatening obesity-related complications currently being treated
- Unable to enroll in an ongoing trial of retatrutide or a comparable investigational drug
You cannot apply on your own. Noom says the request has to come from a treating physician, who confirms that no suitable approved treatment exists and checks ClinicalTrials.gov for an active retatrutide trial. Lilly’s general expanded-access policy promises a response within five business days of receiving the required medical information, according to Noom. Noom also says meeting the criteria does not guarantee an application is approved, and that most people will not qualify.
Can you join a retatrutide trial?
Clinical trials are the main route. Drugs.com says retatrutide is available only to people enrolled in an active trial. Noom reports a separate, narrow expanded access route that a treating physician must request. Drugs.com says people interested in trials can search for active studies on ClinicalTrials.gov. Each trial sets its own eligibility rules, so read the listing and its status before you plan around it. UCHealth also mentions an ongoing trial called TRIUMPH-5, which is comparing retatrutide with tirzepatide.
What is still unknown
- Approval. InCare notes that approval is not guaranteed and that the FDA review can end in approval, rejection, or a request for more data.
- Price. Drugs.com says retatrutide does not have a price. Noom reports that Lilly has said only that it plans to reflect the drug’s overall value to the health care system.
- Long-term safety. Drugs.com says the long-term safety of retatrutide has not been established because it is still investigational.
- Early access details. Noom says Lilly has not said how long treatment would continue or who covers related monitoring.
Practical next steps while you wait
If you want weight-loss treatment now, the approved GLP-1 medicines are a separate decision with their own price and side effects. The retatrutide vs Zepbound page compares approval status and side effects side by side. The willow glp-1 review covers one service’s price and side effects if you want to read about that option.
Bring these questions to a clinician:
- Do I meet the criteria for the FDA’s expanded access pathway, or should I look at approved options first?
- Is there an active retatrutide trial I might be eligible for?
- Which approved weight-loss medicines fit my health history?
- What monitoring would I need, and who would cover it?
By Gut, Gum and Nail Health Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.